2-indanol formate

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-indanol formate
• 英文别名: 2,3-dihydro-1H-inden-2-yl formate
• 化学式: C₁₀H₁₀O₂
• 分子量: 162.188
• InChiKey: SIGRZYAOZJUFCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-茚醇 、 N,N-二甲基甲酰胺 在 硫酰氟 、 caesium carbonate 作用下， 反应 12.0h， 以81%的产率得到2-indanol formate
  参考文献：
  名称：

  SO 2 F 2介导的亲核酰胺羰基和亲电子醇羟基的合成。

  摘要：

  我们发现，随着硫酰氟的促进，酰胺的羰基作为亲核试剂发挥作用，而醇的羟基被活化以作为亲电试剂官能化。这项研究表明，在不使用过渡金属的情况下，酰胺CN键很容易被精密的亲核试剂裂解形成酯CO键。用44个实例证明了广泛的底物范围和出色的官能团相容性，产率高达99％。

  DOI：

  10.1021/acs.orglett.9b03274

文献信息

• Heterocyclic compounds as P2X7 ion channel blockers
  申请人：Shum Patrick

  公开号：US20050026916A1

  公开（公告）日：2005-02-03

  The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.

  本发明涉及一种新的4,5-二苯基-2-氨基-4,5-二氢咪唑衍生物系列，其化学式为II： 其中R、R1、R2、R3、R4、R5、X和Y如本文所定义。本发明还涉及制备这些化合物的方法。本发明的化合物是P2X7离子通道阻断剂，因此在作为药用剂方面具有用途，特别是在治疗和/或预防具有炎症成分的各种疾病方面，包括炎症性肠病、类风湿关节炎以及与中枢神经系统相关的疾病状况，如中风、阿尔茨海默病等。
• The Transformation of Cyclic Alcohols into Cyclic Acetals through a New Oxygen Atom Insertion by Photolysis in the Presence of Lead Tetraacetate and Iodine
  作者：Hiroshi Suginome、Haruka Washiyama、Shinji Yamada

  DOI：10.1246/bcsj.60.1071

  日期：1987.3

  isolated products. Thus, cholesterol gave 4-oxa-A-homocholest-5-en-3-ol and its acetate in a 53% yield. The products differ considerably from those reported by us after the photolysis of the hypoiodites by using mercury(II) oxide and iodine as the reagents for generating the hypoiodites; they also differ from those in the oxidation of the steroidal alcohols with lead tetraacetate alone. The photolysis

  人们发现，在苯中原位生成的甾体环状高烯丙醇（如胆固醇）和环状醇（如 5α-androstan-17β-ol）的次碘酸盐的光解通常会导致前所未有的形成相应的乳醇乙酸酯的产率高达 66%。在大多数情况下，乳醇乙酸酯在分离过程中很容易水解成乳醇，而乳醇是分离的产物。因此，胆固醇以 53% 的产率得到 4-oxa-A-homocholest-5-en-3-ol 及其醋酸盐。产物与我们报道的以氧化汞和碘为试剂产生次碘酸盐光解次碘酸盐后的产物有很大差异；它们也与单独用四乙酸铅氧化甾醇的不同。
• PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140206686A1

  公开（公告）日：2014-07-24

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了Formula (I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
• HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS
  申请人：SHUM Patrick

  公开号：US20080132550A1

  公开（公告）日：2008-06-05

  The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.

  本发明涉及一种新的4,5-二苯基-2-氨基-4,5-二氢咪唑衍生物系列，其化学式为II：其中R、R1、R2、R3、R4、R5、X和Y如本文所定义。本发明还涉及制备这些化合物的方法。本发明的化合物是P2X7离子通道阻滞剂，因此在治疗和/或预防具有炎症成分的多种疾病方面，包括炎症性肠病、类风湿性关节炎以及与中枢神经系统相关的疾病状态，如中风、阿尔茨海默病等方面，具有药物学上的用途。